About 50 results
Open links in new tab
  1. First-Line Camizestrant for Emerging - The New England Journal of …

    Jun 1, 2025 · Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced …

  2. A Crossover Trial of Hospital-Wide Lactated Ringer’s Solution versus ...

    Jun 12, 2025 · Whether lactated Ringer’s solution is clinically superior to normal saline for routine intravenous administration of fluids is uncertain. In an open-label, two-period, two-sequence, cross ...

  3. Survival of Transplanted Allogeneic Beta Cells with No ...

    Aug 4, 2025 · The need to suppress a patient’s immune system after the transplantation of allogeneic cells is associated with wide-ranging side effects. We report the outcomes of transplantation of ...

  4. Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis

    Mar 5, 2025 · Bacterial vaginosis affects one third of reproductive-aged women, and recurrence is common. Evidence of sexual exchange of bacterial vaginosis–associated organisms between …

  5. Lorundrostat Efficacy and Safety in Patients with Uncontrolled ...

    Apr 23, 2025 · Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. In this …

  6. Structured Exercise after Adjuvant Chemotherapy for Colon Cancer

    Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured …

  7. Clinical Practice Topics | The New England Journal of Medicine

    Recognizing Historical Injustices in Medicine and the Journal Tobacco Use Reduction Additional Topics A Accountable Care Organizations Acute Coronary Syndromes Acute Kidney Injury Addiction

  8. Zongertinib in Previously Treated - The New England Journal of Medicine

    Apr 28, 2025 · Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Zongertinib is an oral ...

  9. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis

    Apr 8, 2025 · Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple …

  10. Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous ...

    Jun 22, 2025 · In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to fasting blood glucose levels. A fixed-dose regimen of insulin efsitora alfa...